Comparative Pharmacology
Head-to-head clinical analysis: ACTICORT versus EOHILIA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTICORT versus EOHILIA.
ACTICORT vs EOHILIA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Topical corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive actions. Suppresses cytokine production and inflammatory mediators via glucocorticoid receptor binding.
EOHILIA (budesonide) is a corticosteroid with potent glucocorticoid activity and weak mineralocorticoid activity. It binds to the glucocorticoid receptor, leading to inhibition of inflammatory mediators such as cytokines and arachidonic acid metabolites, thereby reducing inflammation in the esophagus.
5-60 mg orally once daily, or divided twice daily, depending on condition severity and response.
For adults: 0.5 mg/kg IV every 2 weeks, infused over 60 minutes. Maximum single dose: 40 mg.
None Documented
None Documented
1.5-2.5 hours; prolonged in hepatic impairment (up to 10 hours) and renal impairment (up to 6 hours)
Terminal elimination half-life is 52 hours (steady state reached after 10-12 days of daily dosing)
Renal (70% as unchanged drug and metabolites), biliary/fecal (30%)
Renal (70% unchanged drug), fecal (12%) and biliary (5%)
Category C
Category C
Corticosteroid
Corticosteroid